Diabetes News and Research

Latest Diabetes News and Research

New study identifies 15 genetic regions underlying primary biliary cirrhosis

Researchers have provided new clues into the genetics underlying a chronic form of liver disease, called primary biliary cirrhosis, which can lead to transplant surgery for patients.

14 Mar 2011

$HIV infection and increased fracture risk: Study$

HIV infection and increased fracture risk: Study

According to a latest study, adults between ages 25 and 54 infected with HIV, are at increased risk for bone fractures compared to the general population. Until now it was known that low bone mineral density was common in people with HIV, but no concrete proof existed.

14 Mar 2011

Coffee reduces stroke risk: Study

A new study involving nearly 35,000 women published Thursday in Stroke: Journal of the American Heart Association suggests that drinking coffee may lower the risk of stroke.

12 Mar 2011

Otelixizumab Phase 3 DEFEND-1 study in new-onset autoimmune type 1 diabetes does not meet primary endpoint

Tolerx, Inc. and GlaxoSmithKline (GSK) today announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune type 1 diabetes.

11 Mar 2011

ChromaDex pTeroPure Pterostilbene receives 2010 Most Promising Ingredient of the Year award

ChromaDex Corporation, announced today that the Company has been awarded the 2010 North American Health Ingredients Most Promising Ingredient of the Year award by the independent research company, Frost & Sullivan, for its proprietary branded ingredient pTeroPure™ Pterostilbene.

11 Mar 2011

Arena fourth quarter net loss decreases to $28.2 million

Arena Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2010, and reviewed recent developments.

11 Mar 2011

Halozyme Therapeutics 2010 net loss decreases to $53.2 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2010.

11 Mar 2011

Neurogenesis plays a beneficial role in exercise-induced response to stress, sexual behavior and reproduction

Two studies published by an interdisciplinary team of Hong Kong researchers in the current special issue of Cell Transplantation (20:1), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/ , link the regrowth of key adult brain cells (neurogenesis) in two critical areas of the brain to both the benefits of exercise as a stress reducer and also to sexual behavior and reproductive issues.

11 Mar 2011

FMCNA encourages high blood pressure, diabetes people to learn about risk of CKD

Diabetes and high blood pressure are the two leading causes of chronic kidney disease, a health problem that is growing at an alarming rate in the United States. There are 26 million Americans who have CKD, and millions more are at increased risk and may not even know it.

11 Mar 2011

Genentech announces positive outcomes from Lucentis Phase III trial against DME

Genentech, a member of the Roche Group, today announced that two-year results from a pivotal Phase III trial showed patients with diabetic macular edema who received Lucentis experienced rapid and sustained improvement in vision compared to those who received a placebo injection.

11 Mar 2011

NIH awards Avaxia Phase I SBIR grant to develop novel antibody therapeutic for celiac disease

Avaxia Biologics, Inc., a privately-held biotech company using its proprietary platform technology to develop orally-active antibody therapeutics for the treatment of gastrointestinal diseases, announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (NIH), to support the development of a novel antibody therapeutic for celiac disease.

11 Mar 2011

$HIV-infected patients may face increased risk of bone fracture$

HIV-infected patients may face increased risk of bone fracture

Low bone mineral density in HIV-infected patients is common and raises concerns about increased risks of fracture. Although there have been several studies regarding bone mineral density, there have been few data on rates of fracture in this population.

11 Mar 2011

Seattle Children's Hospital inaugurates new dialysis unit

Today, timed with World Kidney Day, Seattle Children's Hospital announced the opening of its newly renovated dialysis unit. The unit will significantly improve patient comfort and safety compared to its predecessor facility, and includes an additional 630 square feet of space for a total of nearly 2,400 square feet.

11 Mar 2011

SAP may serve as effective nanomaterial to prevent prostate cancer spread

When prostate cancer stem cells were enclosed in self-assembling nanomaterials made of peptides, the SAP stopped cancer stem cell colony formation and also stopped the division of cancer cells in laboratory cultures.

11 Mar 2011

Depression is linked with increased risk of developing kidney failure

Depression is associated with an increased risk of developing kidney failure in the future, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

10 Mar 2011

Coffee consumption may reduce risk of stroke in women

Drinking more than a cup of coffee a day was associated with a 22 percent to 25 percent lower risk of stroke, compared with those who drank less, in a study reported in Stroke: Journal of the American Heart Association.

10 Mar 2011

Novartis new MS treatment receives Notice of Compliance in Canada

Novartis Pharmaceuticals Canada Inc. announced today that its new MS treatment, Gilenya, has received Notice of Compliance in Canada.

10 Mar 2011

TGen launches globalCure initiative to fight against pancreatic cancer

In an effort to improve treatment and one day find a cure for pancreatic cancer, the TGen Foundation today joined with key donors and community leaders to announce the creation of globalCure.

10 Mar 2011

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes.

10 Mar 2011

Medtronic resolves FDA warning letters over Mounds View, Juncos facilities

Medtronic, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the company that issues noted in two warning letters -- one from November 2009 regarding the company's Mounds View, Minnesota facility and another from June 2009 regarding the company's manufacturing facility in Juncos, Puerto Rico -- have been resolved.

10 Mar 2011